AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3533455
Drug: Inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol (0.4 mg)
Trial: 2484920
Drug: dihydroquinidine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dihydroquinidine (900 mg/day)
Trial: 2484920
Drug: quinidine (1,650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quinidine (1,650 mg/day)
Trial: 29275580
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: dose-dense TEC× 4 every 2 weeks with G-CSF
Trial: 29275580
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: sequential EC× 4 (dose-dense)-T × 4 every 2 weeks
Trial: 29275580
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: concurrent TEC× 4 every 3 weeks
Trial: 29275580
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: sequential EC× 4-T × 4 every 3 weeks
Trial: 23274145
Drug: Atorvastatin test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin test formulation (generic) 20 mg per day for 8 weeks
Trial: 23274145
Drug: Atorvastatin reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin reference formulation (original) 20 mg per day for 8 weeks
Trial: 23274145
Drug: Atorvastatin test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin test formulation
Trial: 23274145
Drug: Atorvastatin reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin reference formulation
Trial: 15281283
Drug: Anticancer drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticancer drugs (33% off label use)
Trial: 10667492
Drug: IVIG (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (1 g/kg in four divided doses on days 1, 2, 3, and 6)
Trial: 8364347
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg S(+) OXP daily
Trial: 8364347
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg R(‐) OXP daily
Trial: 8364347
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg S(+) OXP single dose (normal controls)
Trial: 8364347
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg R(‐) OXP single dose (normal controls)
Trial: 3090864
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (low to moderate doses)
Trial: 3090864
Drug: Chlordiazepoxide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (10 mg tid, active placebo)
Trial: 20144173
Drug: Non-medication group
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-medication group
Trial: 30952575
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/mL (Gla-300) managed by nurse-assisted patients
Trial: 30952575
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/mL (Gla-300) managed by physicians
Trial: 23020760
Drug: 0.5 L
RxNorm normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 L beetroot (BR) juice
Trial: 23020760
Drug: 0.5 L
RxNorm normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 L placebo (PLA) drink with blackcurrant juice
Trial: 16293396
Drug: 6-week combined
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week combined treatment approach using vocal function exercises (VFEs) and vocal hygiene (VH) education
Trial: 12898761
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection with 1.0 ml of 2% chitosan
Trial: 12898761
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 12.5 mg of prednisolone
Trial: 11303537
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 3 ml 1% l-menthol solution
Trial: 11303537
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation of 3 ml 0.05% l-menthol
Trial: 28513852
Drug: Pentoxifylline (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1200 mg orally before thrombolytic therapy)
Trial: 28513852
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard protocol for treatment of MI)
Trial: 10936631
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment (IPT or NT)
Trial: 2052740
Drug: Controlled-release hydrogel
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release hydrogel polymer prostaglandin E2 pessary (0.6 mg PGE2 per hour)
Trial: 6192652
Drug: H1 receptor
RxNorm normalized name: Histamine H1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 receptor blockade alone
Trial: 6192652
Drug: H1 receptor
RxNorm normalized name: Histamine H1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 receptor blockade in combination with H2 receptor blockade
Trial: 6192652
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor blockade alone
Trial: 25847112
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antidepressants (mainly selective serotonin reuptake inhibitors)
Trial: 19415289
Drug: Multidetector CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidetector CT after oral administration of polyethylene glycol solution (n = 21)
Trial: 19415289
Drug: Multidetector CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidetector CT after administration of methylcellulose via nasojejunal tube (n = 13)
Trial: 15145874
Drug: DDDR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDDR with fixed long AV delay (DDDR-l) (n = 63)
Trial: 1700077
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus vinblastine plus bleomycin (PVB) chemotherapy
Trial: 7377916
Drug: Naloxone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (20 mg, intravenous)
Trial: 30783957
Drug: Baclofen 5%
RxNorm normalized name: Baclofen 5% Topical application Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 5% cream
Trial: 31708152
Drug: Co-trimoxazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (20 mg trimethoprim and 100 mg sulfamethoxazole orally for infants <6 months or <5 kg; 40 mg trimethoprim and 200 mg sulfamethoxazole orally for infants >6 months or >5 kg)
Trial: 27370878
Drug: Pirfenidone (801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (801 mg/day titrated to 2403 mg/day over 16 weeks)
Trial: 27370878
Drug: Pirfenidone with
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone with 2-week titration
Trial: 27370878
Drug: Pirfenidone with
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone with 4-week titration
Trial: 24634424
Drug: Tactile stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tactile stimulation (rubbing the skin adjacent to the injection site or applying pressure)
Trial: 20669666
Drug: Intracoronary administering
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary administering of 10 mL (0.5 mg) tirofiban and 400 mg XST, followed by 36 h continuous intravenous dripping of tirofiban 10 mL/h and 400 mg XST in 250 mL of saline for dripping.
Trial: 20669666
Drug: Intracoronary administering
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary administering of 10 mL (0.5 mg) tirofiban, followed by 36 h continuous intravenous dripping of tirofiban 10 mL/h without XST.
Trial: 12164876
Drug: ET‐A receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET‐A receptor antagonist BQ‐123 (40 nmol/min)
Trial: 12164876
Drug: ET‐B receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET‐B receptor antagonist BQ‐788 (1 and 50 nmol/min)
Trial: 8352038
Drug: Silver acetate
RxNorm normalized name: SILVER ACETATE
DrugBank: Silver (DB12965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver acetate mouth spray, used every 2 hours for 3 weeks
Trial: 8352038
Drug: Placebo spray,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray, used every 2 hours for 3 weeks
Trial: 3676054
Drug: HFJV using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFJV using three frequencies (100, 300 and 600 b.p.m.) via a 1.8‐mm i.d. proximal injector cannula (proximal injection)
Trial: 30173835
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with a continuous beam 660-nm, 75-mW laser applied for 15 seconds at 8 points for a total treatment time of 2 minutes.
Trial: 25044172
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (SLT) alone
Trial: 15811140
Drug: DZX 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZX 100 mg three times daily for 6 days
Trial: 15811140
Drug: DZX 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZX 50 mg three times daily for 6 days
Trial: 15811140
Drug: DZX 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZX 75 mg three times daily for 6 days
Trial: 15811140
Drug: DZX 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZX 50 mg in non-obese men
Trial: 15811140
Drug: DZX 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZX 100 mg in non-obese men
Trial: 6853873
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment program (4 weeks of coping-skills training using behavioral rehearsal and self-instruction training)
Trial: 31347247
Drug: Esomeprazole (ESO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (ESO, 20 mg bid) (group A)
Trial: 24406025
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of ondansetron
Trial: 20574649
Drug: ETN 25
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN 25 mg twice a week and MTX 6‐8 mg/week (E + M group)
Trial: 17310130
Drug: Pilocarpine 20
RxNorm normalized name: pilocarpine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine 20 mg/day orally for 7 days
Trial: 15883634
Drug: Fok1 polymorphism
RxNorm normalized name: ANGELICA POLYMORPHA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fok1 polymorphism of the VDR with Ca intake >800 mg/day
Trial: 15883634
Drug: Fok1 polymorphism
RxNorm normalized name: ANGELICA POLYMORPHA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fok1 polymorphism of the VDR with Ca intake <= 800 mg/day
Trial: 31821750
Drug: Itacitinib (10-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib (10-300 mg, 500 mg, 1000 mg)
Trial: 31196032
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg PO once daily for 6 months during SRT
Trial: 25719991
Drug: Ranibizumab plus
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab plus prompt or deferred focal/grid laser treatment
Trial: 25719991
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection plus focal/grid laser treatment
Trial: 16438751
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg intravenously 3 min before induction of anaesthesia
Trial: 9354348
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 800 mg daily
Trial: 8222508
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (low dose: 1 ng min-1kg-1)
Trial: 8222508
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (high dose: 5 ng min-1kg-1)
Trial: 31898758
Drug: EMG biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG biofeedback therapy applied to tibialis anterior muscles, 5 days a week for 3 weeks in addition to conventional physiotherapy
Trial: 30956111
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration of ivermectin (200 μg/kg) and azithromycin (20 mg/kg)
Trial: 30956111
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration of ivermectin and azithromycin
Trial: 27840352
Drug: Pipemidic acid
RxNorm normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipemidic acid (400 mg bid)
Trial: 27840352
Drug: Phenazopyridine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenazopyridine (200 mg tid)
Trial: 27840352
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac (50 mg bid)
Trial: 18285478
Drug: Amprenavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir (600 mg BID)
Trial: 18285478
Drug: Lopinavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir (400 mg BID) plus ritonavir (100 or 200 mg BID)
Trial: 18285478
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of amprenavir and lopinavir
Trial: 12761806
Drug: Once-daily controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily controlled-release formulation of divalproex sodium
Trial: 12761806
Drug: Commercial enteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial enteric tablet dosed twice-daily
Trial: 9118303
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg orally twice a day)
Trial: 1714950
Drug: MOPP (mechlorethamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) alternating with ABVD (doxorubicin, vinblastine, bleomycin, and dacarbazine) followed by low-dose radiotherapy (RT)
Trial: 1714950
Drug: MOPP alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP alternating with ABVD followed by low-dose RT
Trial: 28423301
Drug: Risankizumab (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (90 mg and 180 mg doses at weeks 0, 4, and 16)
Trial: 28423301
Drug: Ustekinumab (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (45 or 90 mg doses at weeks 0, 4, and 16)
Trial: 28423301
Drug: Risankizumab (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (18 mg, 90 mg, and 180 mg doses)
Trial: 28423301
Drug: Ustekinumab (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (45 or 90 mg doses)
Trial: 24561125
Drug: Liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.2 mg once daily
Trial: 21114607
Drug: Glimepiride 4
RxNorm normalized name: glimepiride 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 4 mg once daily
Trial: 20396719
Drug: Artrofoon treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artrofoon treatment for 2 years
Trial: 14970135
Drug: Alkalinized lidocaine-filled
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkalinized lidocaine-filled ETT cuff with water-soluble gel lubrication (Group G)
Trial: 14970135
Drug: Alkalinized lidocaine-filled
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkalinized lidocaine-filled cuffs (Group G and W)
Trial: 9143860
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1)
Trial: 9143860
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2)
Trial: 8182635
Drug: Supervised group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised group physical therapy (3 hours weekly)
Trial: 8182635
Drug: Unsupervised daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised daily individualized exercises at home (9 months)
Trial: 24121121
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (CMT)
Trial: 8808130
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg fluvoxamine
Trial: 8944409
Drug: Fluvoxamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine treatment
Trial: 11422727
Drug: Fluvoxamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine and paroxetine treatment
Trial: 11422727
Drug: Acute discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute discontinuation
Trial: 8129449
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral flucloxacillin 250 mg/day (group P, n = 18)
Trial: 25156424
Drug: Dried California
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried California Mission figs (120 g/d)
Trial: 21442809
Drug: Routine medicine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medicine, physical therapy, occupational therapy, and other rehabilitation trainings
Trial: 19845037
Drug: Metformin (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (arm A; n = 59)
Trial: 19845037
Drug: Metformin (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (arm A)
Trial: 11742271
Drug: LEV 0.31
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 0.31 mg
Trial: 11742271
Drug: LEV 0.63
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 0.63 mg
Trial: 11742271
Drug: RAC 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC 1.25 mg
Trial: 11742271
Drug: RAC 2.5
RxNorm normalized name: Dolorac 2.5 MG/ML Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC 2.5 mg
Trial: 8359579
Drug: Lysine acetylsalicilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicilate (450 mg i.v.)
Trial: 21512258
Drug: Subcutaneous fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous fondaparinux
Trial: 30284557
Drug: Oral edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral edoxaban
Trial: 26137702
Drug: Xiaoaiping injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoaiping injection (60 mL, i.v., qd)
Trial: 16357551
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy supplemented with partial weight‐bearing gait training twice weekly
Trial: 15124980
Drug: Cinnarizine 20
RxNorm normalized name: cinnarizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 20 mg and dimenhydrinate 40 mg (Arlevert, ARL)
Trial: 15124980
Drug: Dimenhydrinate 50
RxNorm normalized name: dimenhydrinate 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate 50 mg
Trial: 2908307
Drug: All medications
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All medications
Trial: 8642030
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.5% bupivacaine and 1:200,000 epinephrine in saline solution after closure of the wound (Group 2)
Trial: 8642030
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.5% bupivacaine and 1:200,000 epinephrine in saline solution before the incision (Group 1)
Trial: 8642030
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 mL of plain saline solution for both injections, Group 3)